S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Gunmen kill 9 Chinese at mine in Central African Republic
Niinistö: Sweden security OK if Finland joins NATO first
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Nations approve key UN science report on climate change
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Gunmen kill 9 Chinese at mine in Central African Republic
Niinistö: Sweden security OK if Finland joins NATO first
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Nations approve key UN science report on climate change
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Gunmen kill 9 Chinese at mine in Central African Republic
Niinistö: Sweden security OK if Finland joins NATO first
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Nations approve key UN science report on climate change
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Credit Suisse, UBS shares plunge after takeover announcement
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Gunmen kill 9 Chinese at mine in Central African Republic
Niinistö: Sweden security OK if Finland joins NATO first
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Nations approve key UN science report on climate change
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Scottish independence at crossroads in testy SNP leader race
Swiss bank USB is acquiring smaller rival Credit Suisse for over $3 billion
NASDAQ:NLSP

NLS Pharmaceutics - NLSP Stock Forecast, Price & News

$1.50
-0.01 (-0.66%)
(As of 03/17/2023 08:54 PM ET)
Add
Compare
Today's Range
$1.45
▼
$1.59
50-Day Range
$1.30
▼
$1.82
52-Week Range
$0.33
▼
$1.88
Volume
51,900 shs
Average Volume
85,379 shs
Market Capitalization
$17.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

NLS Pharmaceutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
233.3% Upside
$5.00 Price Target
Short Interest
Healthy
0.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.65 out of 5 stars

See Top Rated MarketRank™ Stocks Here

NLSP stock logo

About NLS Pharmaceutics (NASDAQ:NLSP) Stock

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.

Receive NLSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter.

NLSP Stock News Headlines

March 1, 2023 | finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics to Present at the 35th Annual Roth Conference
March 1, 2023 | finance.yahoo.com
NLS Pharmaceutics to Present at the 35th Annual Roth Conference
March 20, 2023 | Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
January 31, 2023 | markets.businessinsider.com
Maxim Group Keeps Their Buy Rating on NLS Pharmaceutics (NLSP)
January 30, 2023 | finance.yahoo.com
NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
January 25, 2023 | finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement
January 25, 2023 | finance.yahoo.com
NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement
January 23, 2023 | finance.yahoo.com
NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity
March 20, 2023 | Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
January 12, 2023 | finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement
January 12, 2023 | finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds
January 12, 2023 | finance.yahoo.com
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement
January 12, 2023 | finance.yahoo.com
NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds
January 11, 2023 | finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics to Participate in Upcoming Investor Conferences
January 10, 2023 | finance.yahoo.com
NLS Pharmaceutics Announces Technology Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Rare Sleep Disorders in Hong Kong
December 20, 2022 | finance.yahoo.com
NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Other Sleep Disorders Through 2037
December 14, 2022 | finance.yahoo.com
NLS Pharmaceutics Announces Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.
December 7, 2022 | finance.yahoo.com
NLS Pharmaceutics Announces Purchase Agreement with BVF Partners L.P. to Raise Aggregate Gross Proceeds of up to $30 Million
December 1, 2022 | finance.yahoo.com
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder
November 23, 2022 | finance.yahoo.com
NLS Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in Europe
November 14, 2022 | finance.yahoo.com
NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice
November 7, 2022 | finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience in the Treatment of Narcolepsy
November 7, 2022 | finance.yahoo.com
NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy
November 2, 2022 | finanznachrichten.de
NLS Pharmaceutics AG: U.S. FDA Grants Orphan Drug Designation for Quilience for the Treatment of Idiopathic Hypersomnia
November 2, 2022 | finance.yahoo.com
U.S. FDA Grants Orphan Drug Designation (ODD) for Quilience(R) (Mazindol ER) for the Treatment of Idiopathic Hypersomnia (IH)
October 5, 2022 | finanznachrichten.de
NLS Pharmaceutics AG: NLS Pharmaceutics Announces $4 Million Private Placement and Conversion of Existing Short-Term Notes
October 5, 2022 | finance.yahoo.com
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
See More Headlines
Receive NLSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter.

NLSP Company Calendar

Today
3/20/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NLSP
CUSIP
N/A
CIK
1783036
Web
www.nlspharma.com
Phone
41-44-512-2150
Fax
41-41-618-8009
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+233.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.59
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.05 per share
Price / Book
30.00

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
-0.83

Key Executives

  • Mr. Alexander Zwyer M.B.A. (Age 54)
    Pres, CEO & Director
  • Mr. Chad C. Hellmann M.B.A.
    Chief Financial Officer
  • Mr. Eric Konofal M.D. (Age 56)
    Ph.D., Chief Scientific Officer
  • Dr. Christian C. Wenger Dr. iur. (Age 59)
    L.L.M., LL.M., Ph.D., Gen. Counsel
  • Ms. Sharon Keys
    Head of Regulatory Affairs
  • Dr. George Apostol M.D. (Age 50)
    Chief Medical Officer and Global Head of R&D

Key Competitors

View All Competitors













NLSP Stock - Frequently Asked Questions

Should I buy or sell NLS Pharmaceutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NLS Pharmaceutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NLSP shares.
View NLSP analyst ratings or view top-rated stocks.

What is NLS Pharmaceutics' stock price forecast for 2023?

3 brokers have issued 12 month price targets for NLS Pharmaceutics' shares. Their NLSP share price forecasts range from $4.00 to $6.00. On average, they expect the company's share price to reach $5.00 in the next year. This suggests a possible upside of 233.3% from the stock's current price.
View analysts price targets for NLSP or view top-rated stocks among Wall Street analysts.

How have NLSP shares performed in 2023?

NLS Pharmaceutics' stock was trading at $1.29 at the start of the year. Since then, NLSP shares have increased by 16.3% and is now trading at $1.50.
View the best growth stocks for 2023 here.

When is NLS Pharmaceutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our NLSP earnings forecast.

When did NLS Pharmaceutics IPO?

(NLSP) raised $20 million in an initial public offering (IPO) on Friday, January 29th 2021. The company issued 3,600,000 shares at a price of $5.00-$6.00 per share. Maxim Group LLC served as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager.

What is NLS Pharmaceutics' stock symbol?

NLS Pharmaceutics trades on the NASDAQ under the ticker symbol "NLSP."

How do I buy shares of NLS Pharmaceutics?

Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NLS Pharmaceutics' stock price today?

One share of NLSP stock can currently be purchased for approximately $1.50.

How can I contact NLS Pharmaceutics?

NLS Pharmaceutics' mailing address is ALTER POSTPLATZ 2, STANS V8, CH-6370. The official website for the company is www.nlspharma.com. The company can be reached via phone at 41-44-512-2150 or via fax at 41-41-618-8009.

This page (NASDAQ:NLSP) was last updated on 3/20/2023 by MarketBeat.com Staff